Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Target K_i: 350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2)

Cell permeable: yes

Primary TargetP38β

General description

A potent and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (IC₅₀ = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC₅₀ = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to block LDL expression in Hep52 cells.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ajizian, S.J., et al. 1999. J. Infect. Dis.179, 939.Singh, R.P., et al. 1999. J. Biol. Chem.274, 19593.Wang, S.W., et al. 1999. Inflamm. Res.48, 533.Gallagher, T.F., et al. 1997. Bioorg. Med. Chem.5, 49.Jiang, Y., et al. 1996. J. Biol. Chem.271, 17920.Kramer, R.M., et al. 1996. J. Biol. Chem.271, 27723.Li, Z., et al. 1996. Biochem. Biophys. Res. Commun.228, 334.Lee, L.C., et al. 1994. Nature372, 739.

Packaging

Packaged under inert gas

1 ml in Glass bottle

Please refer to vial label for lot-specific concentration.

Physical form

A 1 mg/ml solution of SB 202190 (Cat. No. 559388) in anhydrous DMSO.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C).

Warning

Toxicity: Irritant (B)